Current Report · Items 2.02, 9.01 · 8-K

DataMeds AI, Inc.

MEDSNASDAQEQUITYCurrent

Results of Operations and Financial Condition

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Description No. of Exhibit ───────────────────────────────────────────────────────────────────────── 99.1 Press Release of DataMEDS AI, Inc. dated August 17, 2026 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) -2-

Filed Aug 18, 2026Accepted Aug 18, 2026, 7:43 AM EDTCIK 2030763Accession 0001493152-26-038891

View company →Permanent SEC source ↗

Press release in this filing

DataMeds AI Reports Second Quarter 2026 Financials and Provides Business Update →

Company context

We are currently not authorized to issue any shares of preferred stock. The holders of a majority of the issued and outstanding shares of our common stock approved, by written consent dated August 25, 2026, the Blank Check Amendment. Such stockholder approval will be deemed effective 20 calendar days after the date on which a definitive information statement related thereto is first sent or given to our stockholders. We filed a preliminary information statement with the SEC related thereto on August 31, 2026. As of the date of this prospectus, we have not filed a definitive information statement with the SEC or sent or given a definitive information statement to our stockholders. Promptly after the approval of the Blank Check Amendment by our stockholders is deemed effective, we expect to file the Blank Check Amendment with the Delaware Secretary of State and for it to be effective upon filing, and to promptly thereafter file a certificate of designation that designates 25,000 shares of preferred stock as the Series A Preferred Stock. Certain terms of the Series A Preferred Stock are summarized below:

Current securities

MEDSNASDAQ · EQUITY · Current

Historical securities (1)

WGRXNASDAQ · EQUITY · Historical · closed Jul 21, 2026

Recent company filings

Registered securities in this filing

DATAMEDS AI, INC. · 8-K · Filed 2026-08-18

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock, $0.0001 par value per share

Symbol: MEDS
Exchange: NASDAQ
Classification: COMMON
Status: Current

Filing context

Context: AsOf2026-08-17

Dimensions: Not supplied

Accession 000149315226038891 · 1 registered-security cover member

Read the exact SEC filing ↗

Disclosure sections

Items 2.02, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 9.01Item 9.01 - Financial Statements and Exhibits

Filed exhibits (1)

EX-99.1 (by filename) ex99-1.htm

EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 DataMeds AI Reports Second Quarter 2026 Financials and Provides Business Update Health Lives Here app launch with NFL Alumni Health expected in September 2026 ───────────────────────────────────────────────────────────────────────────────────────────────────── Revenues grew 14% reaching $1.779M in Q2/26, beating management projections Corporate name change from Wellgistics Health, Inc. to DataMeds AI, Inc. in July 2026, which led to stock symbol change from ‘WGRX’ to ‘MEDS’ on NASDAQ Capital Markets $6.5 million new funding in June 2026 provided capital to support corporate turnaround Pending transaction with Datavault AI, EOS Technology Holdings, Scilex Holdings and HealthBridge Associates to consolidate patent protected blockchain, biometrics and pharmaceutical-adjunct products intellectual properties to deliver the “Health Lives Here” consumer app, in partnership with NFL Alumni Health (NFLAH), to deliver an effective healthcare experience to patients in rural communities via local independent pharmacies 1:50 reverse split in May 2026 implemented to partially address NASDAQ delisting risk Holder…

Open exhibit ↗

Get the free weekly BCS email.